Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pragmatic trial on the safety and tolerability of an optimized dose of rifampicin in tuberculosis patients
2023-509885-39-00Phase 3Authorised
- Sponsor
- IRCCS Ospedale Sacro Cuore Don Calabria
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3 trial of rifampicin in pulmonary tuberculosis (TB), sponsored by IRCCS Ospedale Sacro Cuore Don Calabria. Primary endpoint: Incidence of hepatotoxicity. Planned start Jan 2024; status: authorised.
02
Drugs
rifampicin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on 2023-509885-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509885-39-00.